Sunshine Biopharma, Inc. (SBFMW) NASDAQ

0.06

-0.0173(-23.86%)

Updated at June 02 01:35PM

Currency In USD

Sunshine Biopharma, Inc.

Address

6500 Trans-Canada Highway

Pointe-Claire, QC H9R 0A5

Canada

Phone

332 216 1147

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Employees

52

First IPO Date

February 15, 2022

Key Executives

NameTitlePayYear Born
Steve N. SlilatyChairman, President & Chief Executive Officer545,9531952
Michel RoyChief Commercial Officer283,1661968
Camille SebaalyCFO, Secretary & Director412,2781959
Malek ChamounChief Development Officer01985
Robert G. FerreiraPresident of Sunshine Bio Investments Inc01962

Description

Sunshine Biopharma, Inc., a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; and SBFM-PL4, an anti-coronavirus treatment compound. It also offers Essential 9, a nutritional supplement tablet; and Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name, as well as develops and markets other science-based nutritional supplements. The company has a license agreement with the University of Georgia to advance the development of its anti-coronavirus lead compound, SBFM-PL4. Sunshine Biopharma, Inc. is headquartered in Pointe-Claire, Canada.